间歇性跛行患者股浅动脉支架置入随机试验的长期结果
瑞典七家血管诊所2010至2020年纳入100例间歇性跛行患者,随机接受股浅动脉直接支架置入联合最佳药物治疗(48例)或单纯最佳药物治疗(52例),随访60个月。支架组36个月时SF-36角色生理与躯体健康汇总评分及步行障碍问卷优于对照组,但60个月时健康相关生活质量无显著差异;交叉率60个月达25%。
要点
- 直接支架置入联合最佳药物治疗在36个月时改善健康相关生活质量,60个月时优势不再可检测。
- 36个月时支架组SF-36角色生理(P=.023)与躯体健康汇总(P=.032)优于对照组,EQ5D无显著差异(P=.52)。
- 60个月时两组进展为慢性肢体威胁性缺血、截肢(2.1% vs 1.9%)与死亡(14.6% vs 15.4%)无差异。
核心结论
- 对于孤立性股浅动脉病变所致间歇性跛行患者,直接支架置入相比单纯最佳药物治疗在36个月内带来健康相关生活质量获益,但60个月时不再可检测,高交叉率影响了最终分析的效力。
研究设计与样本
- 多中心随机对照试验,2010至2020年在瑞典七家血管诊所开展,100例患者随机分为直接支架置入联合最佳药物治疗组(n=48)或单纯最佳药物治疗组(n=52),随访60个月。
主要发现
- 36个月随访时,支架组(n=32)SF-36角色生理评分(P=.023)与躯体健康汇总评分(P=.032) statistically显著优于对照组(n=30),EQ5D评分无显著差异(P=.52)。
- 36个月时支架组步行障碍问卷评分 statistically显著优于对照组(P=.029)。
- 60个月随访时,支架组(n=31)与对照组(n=32)健康相关生活质量无显著差异。
- 60个月时对照组向支架组交叉率为25%。
- 两组进展为慢性肢体威胁性缺血、截肢(2.1% vs 1.9%)与死亡(14.6% vs 15.4%)无差异。
局限性
- 60个月时高交叉率影响了最终分析的效力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Primary stenting of the superficial femoral artery (SFA) in intermittent claudication (IC) has been shown to increase health related quality of life (HRQoL) after 12 and 24 months. An extended follow up of HRQoL 36 and 60 months after randomisation is presented. METHODS: A multicentre randomised controlled trial was conducted at seven vascular clinics in Sweden between 2010 and 2020. One hundred patients randomised to either primary stenting and best medical treatment (BMT; n = 48) or BMT alone (n = 52) were followed for 60 months. HRQoL, assessed by the Short Form 36 Health Survey (SF-36) and EuroQoL 5 dimensions (EQ5D) 36 and 60 months after randomisation, was the primary outcome. Walking Impairment Questionnaire (WIQ) score, re-interventions, progression to chronic limb threatening ischaemia (CLTI), amputation, and death were secondary outcomes. RESULTS: At the 36 month follow up, the stent group (n = 32) had statistically significantly better scores in the SF-36 domain "Role Physical" (p = .023) and the Physical Component Summary (p = .032) compared with the control group (n = 30); however, there was no statistically significant difference in EQ5D scores (p = .52). WIQ was statistically significantly better in the stent group compared with the control group (p = .029) at 36 months. At the 60 month follow up, no statistically significant difference in HRQoL was seen between patients in the stent (n = 31) and control groups (n = 32). Crossover from the control group to the stent group was 25% at 60 months. There were no differences in progression to CLTI, amputation (2.1% vs. 1.9%), or mortality (14.6% vs. 15.4%) between groups. CONCLUSION: In patients with IC caused by isolated SFA lesions, primary stenting conferred benefits to HRQoL until 36 months from treatment vs. BMT alone, but these benefits were no longer detectable at 60 months, where a high crossover rate affected the power of the final analysis.
引用
- Gunnarsson T, Bergman S, Pärsson H, et al. Long Term Results of a Randomised Trial of Stenting of the Superficial Femoral Artery for Intermittent Claudication. Eur J Vasc Endovasc Surg. 2023. PMID: 36642399. doi:10.1016/j.ejvs.2023.01.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。